David H. Solomon
President and Chief Executive Officer
Dr. Solomon joined Zealand September 1st, 2008. Dr. Solomon has extensive experience in pharmacology research, having served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York, NY as well as leadership positions at several biotechnology, pharmaceutical and medical device companies, including Remedy Pharmaceuticals and Critical Diagnostics, both in New York. From 2003-2006, Dr. Solomon led healthcare investing at Carrot Capital Healthcare Ventures.
Most recently, Dr. Solomon served as Chief Operating Officer of Vital Sensors, Inc. Dr. Solomon studied medicine and received his doctorate at Cornell University Medical College and the Sloan-Kettering division of its Graduate School of Medical Sciences, in New York City.
Executive Vice President and Chief Scientific Officer
Effective from 1 October 2013, Dr. Torsten Hoffmann (German, born 1967) joined Zealand from Roche, where he spent 16 years in several managerial positions, including as Head of Discovery Chemistry in the Pharma Research division of the company’s headquarters in Basel.
At the department of Discovery Chemistry at Roche, which he led for eight years, more than 280 peer reviewed publications and 540 patent applications have been documented. Torsten is an inventor of netupitant, a neurokinin 1 receptor antagonist which was FDA approved as Akynzeo® in 2014, in a fixed dose combination with palonosetron for the treatment of cancer-chemotherapy induced nausea and vomiting owned by Helsinn and licensed to Eisai Inc. In addition, Torsten is the author of more than 80 research publications, published conference reports and patent applications.
Torsten studied chemistry at the Heinrich-Heine University in Düsseldorf and received his doctorate at the Eidgenössische Technische Hochschule in Zürich, which was followed by a position as post-doc at the Scripps Research Institute in California. He has received several prizes and awards and has been listed in Marquis’ “Who’s Who in the World” and “Who’s Who in Medicine and Healthcare” since 2007.
He serves on the Advisory Boards of Elsevier Life Sciences, Elsevier SA, Amsterdam, the Netherlands, the Department of Chemistry, University of Basel, Switzerland, the Peptide Therapeutics Foundation, US, the Bolder Peptide Symposium, US, and the Center for Biopharmaceuticals, University of Copenhagen, Denmark.
Senior Vice President and Chief Financial Officer
Mats Blom has a BA in Business Administration and Economics from the University of Lund followed by an MBA from I:E:S:E University of Navarra, Barcelona. Mr. Blom has several years experience as a management consultant at Gemini Consulting and at Ernst&Youngs Transaction Services division.
Mr Blom has held CFO positions at Active Biotech and Anoto both publicly listed on the Nasdaq OMX in Stockholm. Before joining Zealand Pharma A/S March 1st, 2010 Mr. Blom served as Chief Financial Officer at Swedish Orphan International a leading European orphan drug company recently acquired by BioVitrum of Sweden. Mats Blom was appointed Senior Vice President and CFO January 3rd, 2011.
Senior Vice President and Chief Operating Officer
Effective from 1 February 2013, Agneta Svedberg (Swedish, born 1963) joined Zealand from Cantargia AB, a Swedish biotech company, where she has held a position as Chief Executive Officer. Agneta has more than 20 years of experience in drug development from different leadership functions in both biotech and big pharma companies, including more than ten years with Genmab A/S in Copenhagen, where she was Global Head of Clinical Development and held various senior management positions, the last year as Copenhagen site Manager with responsibility for 200 people. Prior to this, she was Head of Clinical Development (Europe) at Oxigene Europe AB and also held managerial positions at Pharmacia & Upjohn AB in Sweden.
Agneta Svedberg holds a M.Sc. in Radiation Physics from Lund University and an Executive MBA from Lund University School of Economics and Management, Sweden.